Eye injections are the most effective treatment available for wet macular degeneration, and they now play a role in slowing dry macular degeneration as well. In clinical studies, roughly 63% of patients with wet macular degeneration maintained or improved their vision after one year of treatment. These injections work by blocking the protein that drives abnormal blood vessel growth and leakage in the back of the eye, and for many people they are the difference between keeping functional vision and losing it.
How the Injections Work
Wet macular degeneration develops when the body produces too much of a protein called VEGF (vascular endothelial growth factor). This protein triggers the growth of fragile, abnormal blood vessels beneath the retina. Those vessels leak fluid and blood into the macula, the part of the retina responsible for sharp central vision. The leakage causes swelling, distortion, and eventually permanent damage to the light-sensing cells you rely on for reading, driving, and recognizing faces.
Anti-VEGF injections deliver medication directly into the gel-like fluid inside the eye, where it seeks out and blocks VEGF molecules before they can bind to receptors on blood vessel cells. By interrupting that signaling chain, the drugs reduce leakage from existing abnormal vessels, shrink macular swelling, and prevent new vessels from forming. The result, in practical terms, is that the wet, swollen tissue in the macula dries out and stabilizes, often allowing vision to partially recover.
Which Medications Are Used
Four FDA-approved medications are currently used for wet macular degeneration injections. Ranibizumab (Lucentis), aflibercept (Eylea), and faricimab (Vabysmo) were all designed specifically for treating the eye. A higher-dose version, Eylea HD, was introduced more recently as a longer-acting option.
Faricimab stands apart because it targets two proteins instead of one. In addition to blocking VEGF, it also blocks angiopoietin-2, a second protein involved in blood vessel instability. This dual action may allow some patients to go longer between injections. In clinical trials, both faricimab and the higher-dose aflibercept allowed certain patients to extend their treatment intervals to every 16 weeks, and some patients on aflibercept 8 mg went as long as 24 weeks between injections.
What the Results Look Like
The short-term numbers are encouraging. After one year of treatment, about 63% of patients maintain stable vision or see improvement. Some people gain back enough visual sharpness to resume activities they had given up, like reading or driving. The gains tend to be most dramatic in the first few months of treatment, when the initial swelling resolves.
Long-term results tell a more nuanced story. A seven-year follow-up study found that 55% of patients overall still had stable or improved vision after nearly seven years of treatment. Patients treated with aflibercept fared somewhat better, with 60% maintaining their vision, compared to 43% of those on ranibizumab. The remaining 45% experienced some degree of vision loss over time, which reflects the reality that macular degeneration is a chronic, progressive disease. The injections slow and often halt the damage, but they don’t cure the underlying condition.
Consistency matters enormously. Patients who stay on schedule with their injections tend to have significantly better outcomes than those who miss appointments or stop treatment early. Even a few months of untreated activity can allow irreversible damage.
Injections for Dry Macular Degeneration
Until recently, there was no treatment at all for dry macular degeneration or its advanced form, geographic atrophy. That changed in February 2023 when the FDA approved pegcetacoplan (Syfovre), the first drug for geographic atrophy. Unlike anti-VEGF drugs, this medication works by calming an overactive part of the immune system called the complement cascade, which gradually destroys retinal cells in dry AMD.
The results are more modest than what anti-VEGF injections achieve for wet AMD. In two large clinical trials, monthly injections reduced the rate at which the damaged area of the retina expanded by 18% to 22% over two years. That means the treatment slows vision loss rather than stopping or reversing it. For a disease that previously had no options, though, this represents a meaningful shift. The injections are given monthly or every other month.
What Getting the Injection Feels Like
The idea of a needle in the eye understandably causes anxiety, but most patients report the experience is far less painful than they expected. The entire procedure takes only a few minutes from start to finish.
Your eye is first numbed with anesthetic drops so you won’t feel sharp pain. The surface of the eye and eyelids are then cleaned with an antiseptic solution to prevent infection. A small device called a speculum holds your eyelids open so you don’t need to worry about blinking. The injection itself uses an extremely thin needle inserted through the white part of the eye, and most patients describe feeling pressure rather than pain. Afterward, the speculum is removed, the eye is rinsed, and you’re done.
Some people find the anticipation and the sensation of the antiseptic flush more uncomfortable than the actual needle. Mild grittiness or a feeling that something is in your eye is common afterward and usually resolves within a day. Artificial tears can help with any dryness or surface irritation.
How Often You’ll Need Treatment
Treatment schedules vary, but nearly all patients start with a loading phase of monthly injections for the first three to four months. This initial burst of treatment brings the disease under control. What happens next depends on which approach your retina specialist uses.
Fixed dosing means you receive injections on a set schedule regardless of how your eye looks at each visit. This was the original approach used in clinical trials and delivers reliable results, but it may mean some patients get injections they don’t strictly need.
Pro re nata (as needed) dosing means you’re monitored regularly, but you only get an injection when there are signs the disease is flaring up. This reduces the total number of injections, but it means treatment comes in response to damage that has already started rather than preventing it.
Treat-and-extend is now the most widely used approach. After the loading phase, your doctor gradually stretches the time between injections, perhaps from four weeks to six, then eight, then longer, as long as the eye stays stable. If signs of activity return, the interval is shortened again. The goal is to find the longest safe gap between treatments that’s specific to your eye. With newer medications, some patients eventually reach intervals of 12 to 16 weeks or even longer.
Risks and Side Effects
Intravitreal injections have a strong safety record across millions of procedures performed worldwide. The most feared complication, a serious internal eye infection called endophthalmitis, occurs in roughly 0.02% to 0.08% of injections. Some large studies have reported rates as low as 0.004%. The careful antiseptic preparation before each injection is specifically designed to keep this risk extremely low.
Common, minor side effects include temporary redness on the white of the eye from the needle entry point, mild soreness, and an increase in floaters that typically settles within a day. You should contact your retina specialist if you develop worsening eye pain, a sudden increase in floaters after the first day, new sensitivity to light, or decreased vision, as these can be signs of a rare but serious complication.
There are generally no activity restrictions after the injection. The main precaution is avoiding anything that could contaminate the eye on the day of treatment, such as swimming or rubbing your eyes with unwashed hands.
Why Staying on Treatment Matters
Macular degeneration is a lifelong condition, and the injections manage it rather than cure it. Stopping treatment when vision feels stable is one of the most common reasons patients eventually lose ground. The abnormal blood vessels in wet AMD don’t disappear permanently. They can reactivate weeks or months after the last injection, and the damage from a flare-up may not be fully reversible.
The seven-year data makes this point clearly: patients who maintained consistent treatment over many years had the best chance of preserving functional vision. Even with ongoing therapy, some gradual decline is possible, but the trajectory is dramatically better than the rapid, severe vision loss that wet AMD causes without treatment. Before anti-VEGF injections became available, wet macular degeneration was one of the leading causes of legal blindness in older adults. That is no longer the case for patients who receive timely, sustained treatment.